Gallacher Capital Management LLC Boosts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Gallacher Capital Management LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 85.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,403 shares of the biopharmaceutical company’s stock after buying an additional 5,245 shares during the quarter. Gallacher Capital Management LLC’s holdings in Halozyme Therapeutics were worth $421,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. First Horizon Advisors Inc. grew its position in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the period. Parkside Financial Bank & Trust bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $64,000. Headlands Technologies LLC grew its stake in shares of Halozyme Therapeutics by 1,068.2% in the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 1,613 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $196,000. Finally, Cetera Trust Company N.A purchased a new position in Halozyme Therapeutics during the fourth quarter valued at $208,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 30,000 shares of company stock valued at $1,196,800. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the topic of several recent analyst reports. The Goldman Sachs Group cut their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, January 18th. TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. TD Cowen began coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price for the company. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Halozyme Therapeutics Stock Performance

HALO traded up $0.09 during midday trading on Friday, reaching $39.91. The company had a trading volume of 902,802 shares, compared to its average volume of 866,867. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a market cap of $5.07 billion, a P/E ratio of 18.91, a P/E/G ratio of 0.47 and a beta of 1.26. The business has a 50-day moving average of $39.99 and a two-hundred day moving average of $37.91.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.